Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-280: Capivasertib + docetaxel vs placebo + docetaxel in mCRPC
CTR20223181Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capivasertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AstraZeneca. Started Dec 2022; status: terminated.
02
Drugs
capivasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20223181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223181.